These developments offer new opportunities for precision modulation and combinatorial therapies in ferroptosis-related neurodegenerative conditions
Healthcare (Basel) (2022) 10(3):487
Ala/Lys ratio has been used as a marker for mitochondrial metabolism 41
When initial therapy proves insufficient, treatment escalation includes: Biologic DMARDs targeting specific inflammatory pathways (TNF inhibitors, IL-6 inhibitors, T-cell costimulation blockers, B-cell depleting agents) Targeted synthetic DMARDs such as JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which carry FDA boxed warnings for serious cardiovascular events, malignancy, and thrombosis [24] [25] Combination DMARD therapy Short-term glucocorticoids for symptom control during treatment initiation Before starting biologic or targeted synthetic DMARDs, screening for tuberculosis and hepatitis B is recommended, along with appropriate vaccinations according to ACR guidelines
Marcin S, Lene T, Richard JW, Marina B, Peter VB, George AWB, Emilio F, Frederique G, Annamaria I, Peter M, Ingrid M, Esperanza N, Wolfgang ASandMaria, Antonietta D